| Original language | English |
|---|---|
| Number of pages | 1 |
| Journal | Annals of Oncology |
| Volume | 29 |
| Issue number | 5 |
| DOIs | |
| State | Published - 1 May 2018 |
| Externally published | Yes |
Fingerprint
Pharmaceutical Preparations
Neoplasms
Cite this
@article{f488465f996c48939658f0b346de93fb,
title = "When is crossover desirable in cancer drug trials and when is it problematic?",
author = "A. Haslam and V. Prasad",
year = "2018",
month = "5",
day = "1",
doi = "10.1093/annonc/mdy116",
language = "English",
volume = "29",
journal = "Annals of oncology : official journal of the European Society for Medical Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "5",
}
Haslam, A & Prasad, V 2018, 'When is crossover desirable in cancer drug trials and when is it problematic?', Annals of Oncology, vol. 29, no. 5. https://doi.org/10.1093/annonc/mdy116
When is crossover desirable in cancer drug trials and when is it problematic? / Haslam, A.; Prasad, V.
In: Annals of Oncology, Vol. 29, No. 5, 01.05.2018.Research output: Contribution to journal › Editorial
TY - JOUR
T1 - When is crossover desirable in cancer drug trials and when is it problematic?
AU - Haslam, A.
AU - Prasad, V.
PY - 2018/5/1
Y1 - 2018/5/1
UR - http://www.scopus.com/inward/record.url?scp=85047609411&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdy116
DO - 10.1093/annonc/mdy116
M3 - Editorial
C2 - 29648572
AN - SCOPUS:85047609411
VL - 29
JO - Annals of oncology : official journal of the European Society for Medical Oncology
JF - Annals of oncology : official journal of the European Society for Medical Oncology
SN - 0923-7534
IS - 5
ER -